2190 Stock Overview
A medical device company, provides neuro- and peripheral-vascular interventional medical devices the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zylox-Tonbridge Medical Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$11.00 |
| 52 Week High | HK$14.66 |
| 52 Week Low | HK$8.62 |
| Beta | 0.51 |
| 11 Month Change | -2.65% |
| 3 Month Change | 3.77% |
| 1 Year Change | -4.68% |
| 33 Year Change | -58.88% |
| 5 Year Change | n/a |
| Change since IPO | -81.67% |
Recent News & Updates
Market Participants Recognise Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Revenues Pushing Shares 27% Higher
Oct 02
Solid Earnings Reflect Zylox-Tonbridge Medical Technology's (HKG:2190) Strength As A Business
Sep 27Recent updates
Market Participants Recognise Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Revenues Pushing Shares 27% Higher
Oct 02Solid Earnings Reflect Zylox-Tonbridge Medical Technology's (HKG:2190) Strength As A Business
Sep 27Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Shares May Have Run Too Fast Too Soon
Apr 23Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Shares Could Be 48% Below Their Intrinsic Value Estimate
Jan 18Does This Valuation Of Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Imply Investors Are Overpaying?
Sep 21There's Reason For Concern Over Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Price
Aug 03We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jun 30Is Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Trading At A 45% Discount?
Mar 08We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jan 19Here's Why We're Not Too Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Jul 06We're Hopeful That Zylox-Tonbridge Medical Technology (HKG:2190) Will Use Its Cash Wisely
Jan 27Here's Why We're Not At All Concerned With Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Oct 05Shareholder Returns
| 2190 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 0.7% | -1.8% | 0.4% |
| 1Y | -4.7% | -36.1% | 12.0% |
Return vs Industry: 2190 exceeded the Hong Kong Medical Equipment industry which returned -36.1% over the past year.
Return vs Market: 2190 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 2190 volatility | |
|---|---|
| 2190 Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 9.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2190 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2190's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 756 | Jonathon Zhao | www.zyloxtb.com |
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices the People’s Republic of China and internationally. The company develops neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracranial access devices. It also develops peripheral-vascular interventional product portfolio covering a spectrum of arterial and venous products comprising stents, balloons, catheters, and filters, as well as covers hemodialysis access, aortic intervention, peripheral embolization intervention, and radiological intervention products.
Zylox-Tonbridge Medical Technology Co., Ltd. Fundamentals Summary
| 2190 fundamental statistics | |
|---|---|
| Market cap | HK$3.59b |
| Earnings (TTM) | HK$27.56m |
| Revenue (TTM) | HK$713.20m |
128.5x
P/E Ratio5.0x
P/S RatioIs 2190 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2190 income statement (TTM) | |
|---|---|
| Revenue | CN¥663.61m |
| Cost of Revenue | CN¥188.36m |
| Gross Profit | CN¥475.26m |
| Other Expenses | CN¥449.61m |
| Earnings | CN¥25.65m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.08 |
| Gross Margin | 71.62% |
| Net Profit Margin | 3.86% |
| Debt/Equity Ratio | 2.4% |
How did 2190 perform over the long term?
See historical performance and comparison